Crinetics Pharmaceuticals (CRNX) traded higher on Thursday after UBS launched its coverage with a Buy recommendation and a 12-month target of $55, citing an attractive entry point following the ...

About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tu ...

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Crinetics Pharmaceuticals, Inc.

Three mid-cap biotechs have become prime acquisition targets, but only one offers what big pharma is hunting for most.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Crinetics Pharmaceuticals stock is a 'Buy' rating due to EU approval and strong initial U.S. uptake of Palsonify for ...

Crinetics Pharmaceuticals (NASDAQ: CRNX) faces the ultimate biotech paradox: Its newly approved drug Palsonify could either justify the stock's $4.3 billion valuation or expose it as dangerously ...

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to ...

View Crinetics Pharmaceuticals Inc CRNX stock quote prices, financial information, real-time forecasts, and company news from CNN.

The biotech unveiled its third-quarter results. They didn't meet analyst expectations, but there was good news in the update. For its third quarter, Crinetics earned $143,000 in revenue, derived fully ...

A director of Crinetics Pharmaceuticals reported that he sold 5,000 shares of the company for a transaction value of approximately $180,761 on March 12, 2026. The sale represented 23.47% of Coelho’s ...

Stifel initiated coverage on Monday on Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel ...